Cambridge Healthtech Institute Announces its Sixth Annual Antibacterial Drug Development

Feb. 23, 2012 - PRLog -- This two day event takes place April 17-18, 2012 in San Diego, CA. The event focuses on For quite some time now, the lack of new antibacterials has been broadly recognized as a major unmet medical need. To successfully tackle antibacterial resistance, screening for novel targets and developing new strategies to interfere with bacteria are just as important as other challenges, including predicting toxicology, selectivity, resistance, permeability and pk of a new lead, and creating new models for optimization of leads and compounds. This conference is designed to bring together executive level scientists from the academic, pharmaceutical and biotech areas to discuss progress, novel insight, lessons learned and current bottlenecks.

Speakers Include:  (partial listing)

-  Herbert Schweizer, Ph.D., Professor, Microbiology, Immunology and Pathology, Colorado State University

-  Jim Palmer, Ph.D., Director, Drug Discovery, Research, Biota Holdings, Ltd.

-  John Finn, Ph.D., CSO, R&D, Trius Therapeutics

-  Ian Critchley, Ph.D., Vice President, Microbiology, Cerexa, Inc.

-  Roya Zoraghi, Ph.D., Research Scientist and Director of Screening, Indel Therapeutics

-  Mike Gordeev, Ph.D., CSO, MicuRX Pharmaceuticals

-  Jutta Heim, Ph.D., Professor, Biotechnology; CSO, Discovery, Evolva SA

-  David Harper, Ph.D., CSO, AmpliPhi

-  Roman Kombarov, Ph.D., Project Manager, ASINEX

-  Ursula Theuretzbacher, Ph.D., Center for Anti-Infective Agents (CEFAIA)

-  Tim Meredith, Ph.D., Infectious Disease Division, Novartis Institute for Biomedical Research (NIBR)

-  Stefan Miller, Ph.D., CEO, Lisando GmbH

-  Joyce Sutcliffe, Ph.D., Senior Vice President, Biology, Tetraphase Pharmaceuticals, Inc.

-  Seungil Han, Ph.D., Senior Principal Scientist, Pfizer, Inc.

-  John S. Mjøen Svendsen, Ph.D., Director, Discovery Research, Lytix Biopharma AS

-  Klaus Dembowsky, M.D., Ph.D., Head, Drug Discovery and Development, CMO, Polyphor Ltd.

-  Thale Jarvis, Ph.D., Vice President, R&D, Crestone, Inc.

For more information, or to register, please visit http://www.drugdiscoverychemistry.com/bac.  Register by March 16 to save!

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
Tracey Fielding
Marketing Manager
Cambridge Healthtech Institute
tfielding@healthtech.com

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.